

116TH CONGRESS
2D SESSION

H. R. 6670

To provide for an exploration of strategies to increase domestic manufacturing and diversify the supply chain of critical drugs, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

MAY 1, 2020

Ms. ESHOO (for herself and Mrs. BROOKS of Indiana) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To provide for an exploration of strategies to increase domestic manufacturing and diversify the supply chain of critical drugs, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Prescription for Amer-
5 ican Drug Independence Act of 2020”.

6 **SEC. 2. NATIONAL ACADEMIES STRATEGIES TO INCREASE**
7 **DOMESTIC MANUFACTURING OF CRITICAL**
8 **DRUGS.**

9 (a) IN GENERAL.—Not later than 14 days after the
10 date of enactment of this Act, the Secretary of Health and

1 Human Services shall enter into an agreement with the
2 National Academies of Sciences, Engineering, and Medi-
3 cine (referred to in this section as the “National Acad-
4 emies”) under which, not later than 90 days after the date
5 of entering into the agreement, the National Academies
6 will—

7 (1) establish a committee of experts who are
8 knowledgeable about drug supply issues, including—

9 (A) sourcing and production of critical
10 drugs;

11 (B) sourcing and production of active
12 pharmaceutical ingredients in critical drugs;

13 (C) the raw materials and other compo-
14 nents for critical drugs; and

15 (D) the public health and national security
16 implications of the current supply chain for
17 critical drugs;

18 (2) convene a public symposium to—

19 (A) analyze the impact of United States
20 dependence on the foreign manufacturing of
21 critical drugs on patient access and care, in-
22 cluding in hospitals and intensive care units;
23 and

24 (B) recommend strategies to end United
25 States dependence on foreign manufacturing to

1 ensure the United States has a diverse and vital
2 supply chain for critical drugs to protect the
3 Nation from natural or hostile occurrences; and
4 (3) submit a report on the symposium's pro-
5 ceedings to the Congress and publish a summary of
6 such proceedings on the public website of the Na-
7 tional Academies.

8 (b) SYMPOSIUM.—In carrying out the agreement
9 under subsection (a), the National Academies shall consult
10 with—

11 (1) the Department of Health and Human
12 Services, the Department of Homeland Security, the
13 Department of Defense, the Department of Com-
14 merce, the Department of State, the Department of
15 Veterans Affairs, the Department of Justice, and
16 any other Federal agencies as appropriate; and

17 (2) relevant stakeholders, including drug manu-
18 facturers, health care providers, medical professional
19 societies, State-based societies, public health experts,
20 State and local public health departments, State
21 medical boards, patient groups, health care distribu-
22 tors, wholesalers and group purchasing organiza-
23 tions, pharmacists, and other entities with experi-
24 ence in health care and public health, as appro-
25 priate.

1 (c) DEFINITIONS.—For the purposes of this section:

2 (1) The term “critical drug” means a drug that
3 is described in subsection (a) of section 506C of the
4 Federal Food, Drug, and Cosmetic Act (21 U.S.C.
5 356c) (relating to notification of any discontinuance
6 or interruption in the production of life-saving
7 drugs).

8 (2) The term “drug” has the meaning given to
9 such term in section 201 of the Federal Food, Drug,
10 and Cosmetic Act (21 U.S.C. 321).

○